Phoenix Bio

HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

2026/01/07

Zhang, B. H. Zhou, Y. Horrigan, S. Luckenbaugh, L. Hu, J. Zoulim, F. Zhang, Y. Y.
Mol Ther Methods Clin Dev. 2025 Nov 19;33(4):101646. doi: 10.1016/j.omtm.2025.101646.

Netrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection

2026/01/07

Wang, Y. Murai, K. Ishida, A. Kawasaki, N. Kuroki, K. Li, Y. Y. Sato, Y. Miura, Y. Takara, K. Kong, L. Shimakami, T. Nio, K. Higuchi, Y.Suemizu, H. Ito, S. Yanagawa, H. Kaneko, S. Yamashita, T. Honda, M.
PLoS Pathog. 2025 Dec 17;21(12):e1013776. doi: 10.1371/journal.ppat.1013776.

Cholesterol uptake capacity of HDL in culture medium of fresh primary human hepatocytes: an in vitro system for screening anti-atherosclerosis drugs focused on HDL functions

2026/01/07

Hata, K. Okada, T. Takahashi, M. Arimatsu, Y. Kawahira, J. Murakami, K. Harada, A. Yoshikawa, N. Inamatsu, M. Kakuni, M.
BMC Res Notes. 2025 Nov 13;18(1):480. doi: 10.1186/s13104-025-07515-6.

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity

2026/01/07

Nakayama, M. Takagi-Maeda, S. Machino, Y. Nihira, K. Inoue, M. Takahashi, N. Usami, K.
Oncol Rep. 2025 Nov;54(5):155. doi: 10.3892/or.2025.8988.

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

2026/01/07

Kawamoto, K. Shimotsuma, Y. Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.

Arch Toxicol. 2025 Sep;99(9):3803-3824. doi: 10.1007/s00204-025-04099-9.

Replication-driven HBV cccDNA loss in chimeric mice with humanized livers

2026/01/07

Zhang, B. H. Zhou, Y. Horrigan, S. Zoulim, F. Hu, J. Zhang, Y. Y.
J Virol. 2025 Nov 6:e0129525. doi: 10.1128/jvi.01295-25.

Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice

2026/01/07

Fujita, Yuito Tsutsui, Haruka Hirabayashi, Manabu Shimojo, Tomofumi Tachibana, Tatsuhiko Emoto, Chie Shindoh, Hidetoshi Terao, Kimio Miyake, Taiji
Drug Metab Dispos. 2025 Oct 17;53(12):100185. doi: 10.1016/j.dmd.2025.100185.

Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

2025/11/27

Yano, J. Kawamoto, K. Shimotsuma, Y. Ogata, K. Matsunaga, K. Abe, J. Fukunaga, S. Osimitz, T. G. Lake, B. G. Asano, H.
Regul Toxicol Pharmacol. 2025 Dec;163:105929. doi: 10.1016/j.yrtph.2025.105929.

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

2025/11/27

Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

2025/11/27

Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

2025/11/27

Takamatsu, S. Morita, C. Sakon, D. Nakamura, K. Hishii, H. Kondo, J. Ueda, K. Miyoshi, E.
Viruses. 2025 Sep 15;17(9):1242. doi: 10.3390/v17091242.

Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment

2025/11/27

Yamazaki, K. Kubara, K. Sugahara, G. Muto, H. Yamamoto, M. Mano, Y. Mitsuhashi, K. Yamasaki, C. Ishida, Y. Tateno, C. Suzuki, Y.
Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466.

日本動物実験代替法学会 第38回年会での弊社発表のご案内

2025/10/29

2025年11月1日(土)~3日(月)にパシフィコ横浜で開催の日本動物実験代替法学会 第38回年会にて、
弊社より研究発表がありますのでご案内申し上げます。

CTRMS 2025でのPXBマウス・PXB-Shizuku関連発表のご案内

2025/10/20

2025年10月22日(水)~25日(土)に虎ノ門ヒルズフォーラムで開催の18th Cell Transplant and Regenerative Medicine Society International Congress 2025(CTRMS 2025)にて、PXBマウス・PXB-Shizuku関連発表がありますのでご案内
申し上げます。

European Society of Gene and Cell Therapyでの弊社発表のご案内

2025/10/07

2025年10月7日(火)~10日(金)にスペインのセビリアで開催のEuropean Society of Gene and Cell Therapy(ESGCT)にて
弊社より研究発表がありますのでご案内申し上げます。

日本薬物動態学会第40回年会でのランチョンセミナー開催及び企業展示のご案内

2025/09/25

2025年10月20日(月)~23日(木)に京都市勧業館「みやこめっせ」で開催されます日本薬物動態学会第40回年会にて、
ランチョンセミナーを開催致します。
企業展示も行いますので、ご来場の方はぜひお立ち寄りください。

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

2025/09/17

Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

Modeling of hepatitis B virus infection spread in primary human hepatocytes

2025/09/17

Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

2025/09/17

Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

2025/09/17

Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.